Why SCD trial monitoring matters in 2026
Sickle cell disease (SCD) is one of the most common severe monogenic disorders worldwide, affecting approximately 300,000 newborns annually and an estimated 100,000 Americans. After decades of limited therapeutic options beyond hydroxyurea and transfusion, the field has undergone a historic transformation driven by gene therapy approvals in 2023 and an explosion of pipeline activity.
The SCD clinical trial landscape in 2026 is among the most dynamic in all of rare disease:
- Gene therapy approvals — Casgevy (exa-cel, CRISPR-based) and Lyfgenia (betibeglogene, lentiviral) received FDA approval in December 2023. Follow-on programs are now testing improved manufacturing, reduced conditioning, and outpatient delivery
- In vivo gene editing — base editing, prime editing, and in vivo CRISPR approaches targeting BCL11A or HBB directly are entering early trials, promising broader access than ex vivo approaches
- HbF induction — BCL11A inhibitors, LSD1 inhibitors, and small molecules targeting γ-globin reactivation represent a parallel non-gene-editing strategy
- Anti-sickling and vaso-occlusion agents — crizanlizumab (now withdrawn from some markets), voxelotor (withdrawn), and newer anti-P-selectin and anti-endothelin agents in development
- Myeloablative conditioning — reduced-toxicity conditioning regimens that preserve fertility and reduce transplant-related mortality are a critical enabling technology being studied
- Allogeneic HSCT — haploidentical and mismatched unrelated donor approaches expanding transplant access
Track every new SCD trial automatically
ClinicalTrials.gov updates daily. Our pipeline monitors it and delivers a clean digest every morning.
Start Free — No Credit CardWhat we monitor for sickle cell disease
Our system pulls from the ClinicalTrials.gov API every day. For an SCD watch profile, you can configure alerts for:
- Condition keywords: "sickle cell disease", "sickle cell anemia", "HbSS", "hemoglobin sickle", "vaso-occlusive crisis", "SCD"
- Drug/target keywords: "BCL11A", "gene editing", "CRISPR sickle", "lentiviral sickle", "hydroxyurea", "crizanlizumab", "voxelotor", "HbF induction" — any target or mechanism you're following
- Phase filter: Phase 1 for early gene therapy programs, Phase 2/3 for near-term competitive data
- Sponsor type: Industry, academic, government (NIH is a major SCD funder), or all
- Status changes: New registrations, enrollment opens, status updates, and results postings
The gene therapy revolution in SCD
The 2023 approval of two gene therapies for SCD marked a watershed moment in medicine. However, the list price (~$2-3M per patient) and the complexity of ex vivo manufacturing have created enormous pressure to develop next-generation approaches with broader access:
- Beam Therapeutics — base editing (BEAM-101) targeting BCL11A enhancer, showing early clinical results
- Graphite Bio / Kamau Therapeutics — direct HBB correction approaches
- Intellia Therapeutics — in vivo CRISPR for SCD using lipid nanoparticle delivery to hematopoietic stem cells
- Regeneron and other companies exploring in vivo BCL11A silencing through RNAi or antisense approaches
- Generation Bio and others developing non-viral delivery mechanisms for broader scalability
The race to develop safer conditioning, in vivo delivery, and manufacturing-scalable approaches will generate dozens of new trial registrations through 2026 and beyond.
Who uses SCD clinical trial monitoring
- Rare disease BD teams — tracking gene therapy, gene editing, and small molecule competitors in SCD
- Hematology investors — monitoring Phase 1/2 initiations for gene therapy and novel SCD programs
- Patient advocacy organizations — tracking available trial options for SCD patients and families
- Academic hematologists and genetic counselors — staying current on trial availability at centers outside their own institution
- NIH and government researchers — monitoring the commercial landscape alongside academic programs
Never miss a new SCD trial registration
Set up your alert profile in 2 minutes. Daily digest to your inbox. Free to start.
Get Free SCD Trial AlertsHow TrialNotify works
We run a direct API connection to ClinicalTrials.gov every morning, collecting all new and updated trials. Our matching engine compares each trial against your profile — condition keywords, drug targets, phase, sponsor type, and study status. Only relevant trials reach your inbox.
Your daily digest includes: trial title, phase, sponsor, current status, enrollment target, primary endpoint, and a direct link to the ClinicalTrials.gov record. No noise, no duplicate alerts.
Pricing
Free: 1 disease/keyword profile, daily email digest, ClinicalTrials.gov monitoring. No credit card required.
Starter — $49/month: 5 disease/keyword profiles, daily digest, phase and sponsor filters.
Pro — $149/month: Unlimited profiles, priority email delivery, digest frequency options. Best for BD teams and investors.